BTK anticorps (Middle Region)

N° du produit ABIN359974

Cet anticorps Lapin Polyclonal détecte spécifiquement BTK dans WB, IHC (p) et EIA. Il présente une réactivité envers Humain.

Aperçu rapide pour BTK anticorps (Middle Region) (ABIN359974)

Antigène: BTK (Bruton Agammaglobulinemia tyrosine Kinase (BTK))

Reactivité: Humain

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp BTK est non-conjugé

Application: Western Blotting (WB), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Enzyme Immunoassay (EIA)

Détail du produit anti-BTK anticorps

Épitope: Middle Region

Specificité: This antibody recognizes BTK.

Purification: Protein G Chromatography, eluted with high and low pH buffers and neutralized immediately, followed by dialysis against PBS.

Immunogène: This antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide selected from the center region of human BTK.

Isotype: Ig Fraction

Information d'application

Indications d'application: ELISA: 1/1,000. Western blotting: 1/100-1/500. Immunohistochemistry: 1/50-1/100.
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user.

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 0.25 mg/mL

Buffer: PBS with 0.09 % (W/V) Sodium Azide as preservative.

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Conseil sur la manipulation: Avoid repeated freezing and thawing.

Stock: 4 °C/-20 °C

Stockage commentaire: Store the antibody undiluted at 2-8 °C for one month or (in aliquots) at-20 °C for longer.

Détails sur BTK

Antigène: BTK (Bruton Agammaglobulinemia tyrosine Kinase (BTK))

Autre désignation: BTK

Sujet: BTK plays a crucial role in B-cell ontogeny. This protein transiently phosphorylates GTF2I on tyrosine residues in response to B-cell receptor cross-linking. Defects in BTK are the cause of X-linked agammaglobulinemia type 1 (XLA). XLA is a humoral immunodeficiency disease which results in developmental defects in the maturation pathway of B-cells. Affected boys have normal levels of pre-B-cells in their bone marrow but virtually no circulating mature B-lymphocytes. This results in a lack of immunoglobulins of all classes and leads to recurrent bacterial infections like otitis, conjunctivitis, dermatitis, sinusitis or fatal sepsis or meningitis within the first years of life.Synonyms: AGMX1, ATK, Agammaglobulinaemia tyrosine kinase, B-cell progenitor kinase, BPK, Bruton tyrosine kinase, Tyrosine-protein kinase BTK

ID gène: 695, 9606

UniProt: Q06187

Pathways: Fc-epsilon Receptor Signaling Pathway, Hormone Transport, Activation of Innate immune Response, Regulation of Leukocyte Mediated Immunity, Production of Molecular Mediator of Immune Response, Toll-Like Receptors Cascades, BCR Signaling